CYP3A4 and Miyoshi myopathy: In this context, at least the use of the co-analgesic dexamethasone, which is the most commonly used steroid in spinal cord compression and is a weak CYP3A4 inducer, does not interfere with MM treatment, as its administration did not affect the exposure to bortezomib in MM patients [58].